



基亞生物科技股份有限公司
MEDIGEN BIOTECHNOLOGY CORP.

Medigen BioMedical Group

Innovations for a Better Life





Medigen BioMedical Group

History and Milestones

Cultivating in Biotechnology for 15 years

History

- 1999 Medigen Biotechnology Corp. (MBC) founded
- 2000 Established strategic alliance with Progen Pharmaceuticals in Australia for the development of novel cancer therapeutics
- 2005 Established nucleic acid test (NAT) business, and acquired Texas BioGene Inc, USA
- 2007 Acquired Hao-Yuan in Shanghai, China
- 2009 Started cell-based vaccine R&D projects
- 2011 Medigen Biotechnology Corp. (MBC) obtained approval to go public
- 2012 Perkin Elmer acquired MBC's subsidiary (Hao-Yuan)
Established native human monoclonal antibody platform
Spun-off vaccine business into a subsidiary, Medigen Vaccine Biologics Co. (MVC)
- 2013 Completed PI-88 phase III subjects' recruitment
- 2014 MBC acquired Winston Biopharm Corp. for drug production
The initiation in construction of vaccine plant for MVC in Hsinchu Biomedical Park
Grand Opening of TBG Biotechnology (Xiamen) Inc. and its factory in China
MVC entered phase II study for enterovirus vaccine
Winston obtained PIC/S GMP certification from TFDA
- 2015 MBC announced stock swap between its subsidiary, TBG Inc., and Progen Pharmaceuticals
Winston commended by TFDA for the effort towards drug shortage management
MVC entered phase I/II study for pandemic influenza H7N9 vaccine





Medigen BioMedical Group

Vision

Innovations for a Better Life

Medigen Biomedical Group upholds the vision of "Innovations for a Better Life" focusing on the development of small molecular drugs, human native monoclonal antibodies, molecular diagnostics, cell-based vaccines, biologics, and patented generic drugs. We believe that, through our core values of "compassion, integrity, innovation and professionalism", Medigen will become Asia leading biotechnology company.





Medigen BioMedical Group

Global Location

Local footing, Global thinking




Texas, USA



Cayman Islands



Xiamen, China



M M_v
Taipei


TBG Winston
New Taipei City

M_v
Hsinchu

TBG
Melbourne, Australia

Winston
Tainan

- M** Medigen Biotechnology Corp.
- TBG** TBG Biotechnology Corp.
- M_v** Medigen Vaccine Biologics Co.
- Winston** Winston Biopharm Corp.





Medigen BioMedical Group

Medigen Biotechnology Corp.

Top research & development team

Medigen Biotechnology Corp. was established in late 1999. We are focused on new innovative drug discovery and drug development.

Drug Discovery


In our novel platform technology for the discovery and development of human native monoclonal antibodies, we can immortalize human B cells ex vivo at an efficiency up to 90 percent. With the technology at hand, it becomes feasible to screen for high affinity and avidity therapeutic monoclonal antibodies directly from human B cells.

Drug Development


Our highly qualified team members are professionally equipped with medicinal and life science background. The team is experienced in conducting clinical trials under ICH guidelines and has experience in conducting phase I, II and III multi-national trials.

Pipeline


Medigen's expertise ranges from drug discovery to clinical trial



Native Human mAb Platform Technology



Business Model for Drug Development





Medigen BioMedical Group

TBG Biotechnology Corp. Accuracy, Efficiency, Quality

TBG Inc. was established in 2005 as a holding company in the Cayman Island. After acquiring the Human Leukocyte Antigen (HLA) Typing technology, TBG committed the commercialization of this technology. This included, the establishment of the ISO13485 quality management system, production processes, quality control analysis, securing quality vendors, application of international In Vitro Diagnostic (IVD) certifications with the US FDA, European CE Mark, and Taiwan's Department of Health registration. By 2007, TBG became one of the first Asian biotechnology company to provide HLA typing reagents.

TBG currently has 3 subsidiaries responsible for the general operation, product R&D, IVD regulations, production, marketing, sales and customer service. With a RMB market value of 20 billion dollars, China's Nucleic Acid Testing (NAT) market continues to experience rapid growth with a focus in infectious diseases, oncology, and hereditary diseases. TBG is determined to cater to these applications by providing a fully automated NAT platform.



TBG Taiwan



Medigen BioMedical Group

Expert in Molecular Diagnostics



Thousands of samples in Taiwan were processed each year for HLA typing. Unfortunately, most of them were not processed and reported under international accredited laboratories. In response, TBG decided in 2007 to setup a HLA typing laboratory in Taipei City with accreditation by the American Society of Histocompatibility and Immunogenetics (ASHI). By 2008, TBG successfully obtained the accreditation and became the second ASHI accredited laboratory in Asia catering to the HLA typing needs of the local cord blood banks.

In 2007, the blood screening market in China had revealed immense potential for the NAT technology and platform. By acquiring China Shanghai Haoyuan, TBG was able to develop a 3-in-1 (HIV/HBV/HCV) real-time PCR diagnostics kit in combination with a fully automated blood screening workstation within 2 years. By 2010, TBG received the SFDA clearance on the blood screening products and became the first vendor to identifying an HIV blood donor while still within the window period.



TBG Xiamen

Within the last few years, TBG has mastered the operation, production, and certification of IVD products in China. Particularly, TBG has accumulated sales channels, customer connections, and a strong awareness of IVD market trends. After careful consideration and planning, TBG has chosen Xiamen District in China with its culture similarity to Taiwan, as our China base for product development and manufacturing



Medigen BioMedical Group

Medigen Vaccine Biologics Co.

Fortify Health Security and Welfare

Medigen Vaccine Biologics Co. is devoted to vaccine development and production. Founded in 2012, MVC has successfully established cell-based platforms for pandemic influenza H5N1, H7N9, and Enterovirus 71 vaccines. Our goal is to provide quality health care products to all Taiwanese people as well as neighboring countries with the vision of building a better world.

Taiwan's first PIC/S GMP cell-based vaccine factory

MVC's factory is located at Hsinchu Biomedical Park. It'll become the first PIC/S GMP cell-based vaccine manufacturing facility in Taiwan after completion. The construction is estimated to be completed by the end of 2015, and pilot production is likely to be initiated in 2016. The designed production capacity is up to ten million doses per year.

International standard

- Designed by NNE Pharmaplan (Denmark)
- In accordance with PIC/S GMP, EMA

Multi-product facility

- Two production lines, vaccines and recombinant proteins
- A filling & package suite for vials and prefilled syringes

Flexible configuration

- The protein production line can be switched to vaccine production during pandemic.





Cell-based technology


Compared with traditional manufacturing process, cell-based technology is superior in the production consistency, flexibility and versatility. Besides established influenza and Enterovirus 71 vaccine production, our cell-based production platform is capable of producing Japanese Encephalitis vaccine, Rotavirus vaccine, and many more.

Product development: vaccines & recombinant proteins

Currently, the phase I of pandemic flu H5N1 vaccine was completed in 2013 and H7N9 vaccine has entered phase II clinical development in 2015. Enterovirus 71 vaccine for hand-foot-mouth disease has entered phase II clinical development and is expected to enter phase III in 2016. MVC is also developing recombinant protein drugs to provide versatile product portfolio. MVC aims to become pharmaceutical R&D and production center in Asia-Pacific area, providing quality healthcare for better public welfare.

Innovation for a better and healthier life

With a diverse product portfolio, MVC has capabilities in resource mobilization, R&D, and clinical development. With its innovative technologies, MVC strives to become the leading pharmaceutical company in Asia-Pacific with the mission of protecting the welfare of all communities.





Medigen BioMedical Group

Winston Biopharm Corp.


A PIC/S GMP Certified Site



Founded in 1974, Winston Biopharm Corporation develops, produces, and markets sterile and non-sterile generics, along with hormonal drugs. Under PIC/S GMP, products are manufactured at a high international standard. After celebrating 40 years of operation, Winston joined Medigen Biotechnology Corp. in January 2014.

Winston's current product line covers medicines, food, cosmeceuticals, and ophthalmic related products. They have six major sales channels including over-the-counter (OTC) pharmacy stores, general practice (GP) clinics, hospitals, OEM/OBM foundry, medical aesthetics (MA), and an international trading group for domestic and international biotech pharmaceutical markets.

To obtain presence into China's market, Winston has registered many products including medicines, food, and medical devices. Export began in 2015. Winston is proactively looking for partners in Europe, US, Japan and ASEAN countries for international market export. At the same time, Winston is actively seeking partnerships with international pharmaceutical companies as OEM/ OBM partners as well as distributors in Taiwan.



Medigen BioMedical Group

A Leading Brand in Ophthalmology

Aging with excessive eye contact using electronic devices is becoming a global problem. Winston positions itself as a professional vision care solution provider with the goal to become a leader in this sector in Taiwan. Winston's products include eye drops, food supplements (eg: Lutein sustained-release tablets), and ophthalmic medical devices such as orthokeratology lenses and corneal topography.



Chairman's Message

Medigen Biotechnology Corp. was established in late 1999. Our philosophy is "compassion, integrity, innovation and professionalism". As a starting point, we consider the well-being of humanity, insisting that we take responsibility for guarding human life and health with a constant endeavor to fight for quality and dignity. We aim to see life blossom for ourselves and for others.

Compassion * Integrity * Innovation * Professionalism

For 15 years, Medigen has been constantly strengthening its research and development capability, hardware equipment, and technical ability. We do this in order to undertake the responsibilities independently in the field of molecular diagnostics, clinical trials, product regulation, and certification, medication manufacture with PIC/S standard, and regional marketing ability. Now, Medigen is a comprehensive biopharmaceutical corporation including; Medigen Biotechnology Corporation, Medigen Vaccine Biologics Corporation, TBG Incorporation, and Winston Biopharm Corporation.

Innovations for a better life

Medigen upholds the vision of "Innovations for a better life." We believe that through cooperation and integration to reinforce international competitiveness, Medigen will become one of the most important players in the pharma biotechnology industry not only in Asia, but worldwide.



A handwritten signature in black ink, which appears to read "Stanley Chang".

Stanley Chang M.D., Ph.D.

Innovations for a Better Life





Medigen Biotechnology Corp.

14F, No.3, Park St., Nangang Dist.,
Taipei City 11503, Taiwan
T e l : +886-2-7736-1234
F a x : +886-2-7736-1233
Web : www.medigen.com.tw

TBG Biotechnology Corp.

13F, No.237, Sec. 1, Datong Rd., Xizhi
Dist., New Taipei City 22161, Taiwan
T e l : +886-2-7741-7777 #725
F a x : +886-2-7741-7722
Web : www.texasbiogene.com

Medigen Vaccine Biologics Co.

7F., No.16, Ln. 120, Sec. 1, Neihu Rd.,
Neihu Dist., Taipei City 11493, Taiwan
T e l : +886-2-7745-0830
F a x : +886-2-2658-8980
Web : www.medigenvac.com

Winston Biopharm Corp.

No.117, Ren Ai St., Yongkang Dist.,
Tainan City 71072, Taiwan
T e l : +886-6-2533124
F a x : +886-6-2533116
Web : www.winston.com.tw



基亞生物科技股份有限公司
MEDIGEN BIOTECHNOLOGY CORP.

